“SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent Benefit across Age and Frailty, With No Excess Hypoglycaemia”. Diabzen, vol. 4, no. 15, July 2026, pp. 28-29, https://thediabzen.com/index.php/d/article/view/57.